Upping the game in autoimmune disease
Choices, choices…
During the ongoing American College of Rheumatology (ACR24) conference held in Washington DC, there has been a wide choice of potential new treatments being investigated in refractory autoimmune diseases with several products from the oncology space.
These include bispecific T cell engagers, ex vivo and in vivo CAR-Ts, CAR-NKs, TCRs, and even ADCs.
There’s always more than one way to skin a cat – yet do they all look the same or even produce similar results?
In our latest in-depth look at the emerging preclinical and clinical data, we highlight quite a few red and green flags to watch out for in Part 1 of our ACR coverage…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
